Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B known ✓ | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.40 |
| ▸ | GAA known ✓ | P10253 | 3/20 | 0.38 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.37 |
| ▸ | CYP19A1 known ✓ | P11511 | 1/20 | 0.36 |
| ▸ | TERT | O14746 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 6/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.40 |
| ▸ | MAPT | P10636 | 6/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.39 |
| ▸ | HTT | P42858 | 4/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL971391 | 0.95 | TERT (0.58) | TERTL3MBTL1MEN1KMT2ANPC1 | |
| SCHEMBL129370 | 0.95 | TERT (0.61) | TERTL3MBTL1MEN1KMT2ANPC1 | |
| SCHEMBL12532442 | 0.87 | TERT (0.53) | TERTL3MBTL1MEN1KMT2ANPC1 | |
| SCHEMBL1470931 | 0.87 | TERT (0.53) | TERTL3MBTL1MEN1KMT2ANPC1 | |
| Iodide SCHEMBL1470324 | 0.86 | TERT (0.51) | TERTL3MBTL1MEN1KMT2ANPC1 | |
| SCHEMBL129138 | 0.81 | TERT (0.44) | TERTL3MBTL1MEN1KMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL5144530 | 0.81 | TERT (0.41) | TERTL3MBTL1MEN1KMT2ANPC1 | |
| Bromide SCHEMBL5791833 | 0.80 | TERT (0.43) | TERTL3MBTL1MEN1KMT2ANPC1 | |
| SCHEMBL128425 | 0.79 | TERT (0.42) | TERTL3MBTL1MEN1KMT2ANPC1 | |
| SCHEMBL127217 | 0.79 | TERT (0.42) | TERTL3MBTL1MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11116772-B2 | Medical methods utilising high purity diaminophenothiazinium compounds | WISTA LABORATORIES LTD. (SG) | 2021-09-14 | — | — | US | disclosed |
| US-20200268767-A1 | MEDICAL METHODS UTILISING HIGH PURITY DIAMINOPHENOTHIAZINIUM COMPOUNDS | WISTA LABORATORIES LIMITED (SG) | 2020-08-27 | — | — | US | disclosed |
| EP-3564223-A1 | METHODS OF CHEMICAL SYNTHESIS AND PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INCLUDING METHYLTHIONINIUM CHLORIDE (MTC) | WisTa Laboratories Ltd. (SG) | 2019-11-06 | — | — | EP | disclosed |
| EP-2322517-B1 | METHODS OF CHEMICAL SYNTHESIS AND PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INCLUDING METHYLTHIONINIUM CHLORIDE (MTC) | WISTA LAB LTD (SG) | 2019-04-24 | — | — | EP | disclosed |
| US-20180078562-A1 | MEDICAL METHODS UTILISING HIGH PURITY DIAMINOPHENOTHIAZINIUM COMPOUNDS | WISTA LABORATORIES LTD. (SG) | 2018-03-22 | — | — | US | disclosed |
| US-9801890-B2 | Medical methods utilising high purity diaminophenothiazinium compounds | WISTA LABORATORIES LTD. (SG) | 2017-10-31 | — | — | US | disclosed |
| US-20170209456-A1 | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC) | WISTA LABORATORIES LTD. (SG) | 2017-07-27 | — | — | US | disclosed |
| US-9555043-B2 | High purity diaminophenothiazinium compounds including methylthioninium chloride (MTC) | WISTA LABORATORIES LTD. (SG) | 2017-01-31 | — | — | US | disclosed |
| US-20160129009-A1 | HIGH PURITY DIAMINOPHENOTHIAZINIUM COMPOUNDS INCLUDING METHYLTHIONINIUM CHLORIDE (MTC) | WISTA LABORATORIES LTD. (SG) | 2016-05-12 | — | — | US | disclosed |
| US-9242946-B2 | High purity diaminophenothiazinium compounds including methylthioninium chloride (MTC) | WISTA LABORATORIES LTD. (SG) | 2016-01-26 | — | — | US | disclosed |
| EP-1799662-B1 | METHODS OF CHEMICAL SYNTHESIS AND PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INCLUDING METHYLTHIONINIUM CHLORIDE (MTC) | WISTA LAB LTD (SG) | 2013-04-17 | — | — | EP | disclosed |
| EP-2322517-A1 | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC) | Wista Laboratories Ltd. (SG) | 2011-05-18 | — | — | EP | disclosed |
| US-20110021510-A1 | METHODS OF CHEMICAL SYNTHESIS AND PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INCLUDING METHYLTHIONINIUM CHLORIDE (MTC) | WISTA LABORATORIES LTD. | 2011-01-27 | — | — | US | disclosed |
| US-7790881-B2 | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC) | WISTA LABORATORIES LTD. (SG) | 2010-09-07 | — | — | US | disclosed |
| US-7737138-B2 | Methods of treatment of a tauopathy condition comprising the use of thioninium compounds | WISTA LABORATORIES LTD. (SG) | 2010-06-15 | — | — | US | disclosed |
| US-20080207603-A1 | Methods of Chemical Synthesis and Purification of Diaminophenothiazinium Compounds Including Methylthioninium Chloride (Mtc) | WISTA LABORATORIES LTD. | 2008-08-28 | — | — | US | disclosed |
| EP-1799662-A2 | METHODS OF CHEMICAL SYNTHESIS AND PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INCLUDING METHYLTHIONINIUM CHLORIDE (MTC) | Wista Laboratories Ltd. (SG) | 2007-06-27 | — | — | EP | disclosed |
| US-20060287523-A1 | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC) | WISTA LABORATORIES LTD. (SG) | 2006-12-21 | — | — | US | disclosed |
| WO-2006032879-A2 | METHODS OF CHEMICAL SYNTHESIS AND PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INCLUDING METHYLTHIONINIUM CHLORIDE (MTC) | WISTA LABORATORIES LTD. (SG) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11116772-B2 | Medical methods utilising high purity diaminophenothiazinium compounds | MGMT, MAPT, TST | PDE3B 1713/4885PDE3A 1953/4885GAA 822/4885 |
| US-20160129009-A1 | HIGH PURITY DIAMINOPHENOTHIAZINIUM COMPOUNDS INCLUDING METHYLTHIONINIUM CHLORIDE (MTC) | MGMT, TST, MAPT | PDE3B 1799/4885PDE3A 2209/4885GAA 1694/4885 |
| US-20080207603-A1 | Methods of Chemical Synthesis and Purification of Diaminophenothiazinium Compounds Including Methylthioninium Chloride (Mtc) | MGMT, MAPT, CRBN | PDE3B 2330/4885PDE3A 2536/4885GAA 2629/4885 |
| US-20170209456-A1 | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC) | MGMT, TST, MAPT | PDE3B 2321/4885PDE3A 2667/4885GAA 1466/4885 |
| US-20060287523-A1 | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC) | MGMT, MAPT, TST | PDE3B 2494/4885PDE3A 2828/4885GAA 1580/4885 |
| US-20180078562-A1 | MEDICAL METHODS UTILISING HIGH PURITY DIAMINOPHENOTHIAZINIUM COMPOUNDS | MGMT, MAPT, TST | PDE3B 1629/4885PDE3A 1905/4885GAA 916/4885 |
| US-20110021510-A1 | METHODS OF CHEMICAL SYNTHESIS AND PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INCLUDING METHYLTHIONINIUM CHLORIDE (MTC) | MGMT, TST, MAPT | PDE3B 2524/4885PDE3A 3061/4885GAA 1607/4885 |
| US-20200268767-A1 | MEDICAL METHODS UTILISING HIGH PURITY DIAMINOPHENOTHIAZINIUM COMPOUNDS | MGMT, MAPT, TST | PDE3B 1629/4885PDE3A 1905/4885GAA 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.